Health Condition 1: G473- Sleep apnea
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients of Obstructive Sleep Apnea with AHI of 5 and more with no active infections in 4 weeks prior to recruitment with Body Mass Index of at least 20 kg/m2 and Epsworth Sleepiness Score of at least 6.
Exclusion criteria
Exclusion criteria: Refusal to participate Refusal of PAP therapy Allergy to sulfonamides Central sleep apnoea syndromes, dominant Cheyne-Stokes respiration, or significant sleep disorders including periodic limb movements or parasomnia Patients who had received OSA treatment within 4 weeks of the baseline visit Unstable pulmonary or gastrointestinal disease, Severe congestive heart failure, a history of life-threatening arrhythmias, severe cardiomyopathy Significant chronic kidney disease or hepatic disease Potassium levels less than 3 mmol/L Sodium levels less than 125 mEq/L History of mental illness or those on Amphetamines Drug or alcohol abuse, use of sedatives, severe cognitive impairment or Concurrent oncological diseases. Seizure disorders Prior to the treatment with AZM it will be confirmed that no obvious causes of upper airways obstruction have been detected in the nose, throat or lower jaw by examinations performed at the Department of Otorhinolaryngology.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in Apnea Hypopnea Index with Positive airway Pressure and add on AcetazolamideTimepoint: 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in Pittsburgh Sleep Quality Index with add on Acetazolamide Changes in arterial blood pH, HCO-, and gases with add on Acetazolamide Changes in the sleep parameters with add on Acetazolamide Side effect profile of Acetazolamide Timepoint: 4 weeks | — |
Countries
India
Contacts
King Georges Medical University